Research Article | Open Access
Carla Tripisciano, Tanja Eichhorn, Stephan Harm, Viktoria Weber, "Adsorption of the Inflammatory Mediator High-Mobility Group Box 1 by Polymers with Different Charge and Porosity", BioMed Research International, vol. 2014, Article ID 238160, 8 pages, 2014. https://doi.org/10.1155/2014/238160
Adsorption of the Inflammatory Mediator High-Mobility Group Box 1 by Polymers with Different Charge and Porosity
High-mobility group box 1 protein (HMGB1) is a conserved protein with a variety of biological functions inside as well as outside the cell. When released by activated immune cells, it acts as a proinflammatory cytokine. Its delayed release has sparked the interest in HMGB1 as a potential therapeutic target. Here, we studied the adsorption of HMGB1 to anionic methacrylate-based polymers as well as to neutral polystyrene-divinylbenzene copolymers. Both groups of adsorbents exhibited efficient binding of recombinant HMGB1 and of HMGB1 derived from lipopolysaccharide-stimulated peripheral blood mononuclear cells. The adsorption characteristics depended on particle size, porosity, accessibility of the pores, and charge of the polymers. In addition to these physicochemical parameters of the adsorbents, modifications of the molecule itself (e.g., acetylation, phosphorylation, and oxidation), interaction with other plasma proteins or anticoagulants (e.g., heparin), or association with extracellular microvesicles may influence the binding of HMGB1 to adsorbents and lead to preferential depletion of HMGB1 subsets with different biological activity.
High-mobility group box 1 protein (HMGB1) is a ubiquitous nonhistone DNA binding protein with distinct intra- and extracellular functions. It is crucial for nuclear architecture and has been implicated in DNA replication, repair, and transcription. It acts as a sentinel for nucleic acid-mediated immune responses [1, 2] and as a pathogenic inflammatory mediator during sterile and infectious injury [3–6].
Extracellular HMGB1 is either derived from passive release by injured or necrotic cells or derived from active secretion by immune cells, such as monocytes and macrophages [7–9], or natural killer cells [10, 11] after exposure to pathogen-associated molecular patterns including lipopolysaccharide (LPS) and inflammasome agonists [12, 13]. Secretion of HMBG1 from monocytes/macrophages starts 8–12 h after ligation of cell surface receptors, which represents a significantly delayed release as compared to most other inflammatory mediators produced by these cells, fostering interest in HMGB1 as a target for therapy [3, 14, 15].
HMGB1 secretion is regulated by phosphorylation and acetylation of its two nuclear localization sequences (NLS) [8, 16, 17]. Cell stress and inflammation induce NLS acetylation of HMGB1, resulting in its cytoplasmic accumulation, loading into secretory lysosomes, and release by exocytosis . Secreted HMGB1 acts through various pattern-recognition receptors including the receptor for advanced glycation end products (RAGE), toll-like receptors TLR-2, TLR-4, and TLR-9, T-cell immunoglobulin domain and mucin domain 3 (TIM-3), and CXC chemokine receptor type 4 (CXCR-4) [19–24].
While the secretion of HMGB1 is regulated by phosphorylation and acetylation, its extracellular biological activity and interaction with different receptors depend on the redox state of three conserved cysteine residues at positions 23, 45, and 106. With these residues in a reduced form, HMGB1 induces chemotaxis. With a disulfide bridge between C23 and C45 and a free sulfhydryl at position 106, HMGB1 interacts with toll-like receptor 4 (TLR-4) to stimulate cytokine production, while it loses its biological activity in its completely oxidized form [25, 26].
The depletion of HMGB1 by extracorporeal therapies, such as hemofiltration with porous membranes  or hemoperfusion with adsorption columns has been reported [28, 29]. As HMGB1 possesses two DNA binding domains that interact with negatively charged groups, we tested different anionic polymers for their ability and capacity to bind HMGB1, compared their adsorption efficiency to neutral polystyrene divinylbenzene-based polymers, and correlated the binding characteristics to the physicochemical properties of the polymers. We show here that porosity, size distribution, hydrophobicity, and effective charge density as well as the distribution and accessibility of functional groups on the adsorbent surface are critical determinants of the adsorption characteristics. This implies that a given polymer may preferentially bind subsets of molecules with different posttranslational or oxidative modifications and with different biological activity.
2. Materials and Methods
2.1. Chemicals and Reagents
Recombinant human HMGB1 was purchased from R&D Systems (Minneapolis, USA). Cell culture medium 199 (M199), phosphate-buffered saline (PBS), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), penicillin-streptomycin (PS), and lipopolysaccharide (LPS) from E. coli (O55:B5) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Unfractionated heparin (5000 IU/mL) was from Baxter (Vienna, Austria).
Venous blood was drawn into tubes containing 3.8% trisodium citrate (Vacuette, Greiner Bio-One, Kremsmuenster, Austria) from healthy adult volunteers after written informed consent. Plasma was obtained by centrifugation of the whole blood at 2000 ×g for 10 min at room temperature.
Negatively charged and neutral adsorbents of different particle sizes and porosities were tested in this study. PSDVB-16 and PSDVB-30 (trade names CG161 and CG300; both from Rohm & Haas/Dow Chemical), as well as PVP-PSDVB (trade name Cytosorb; Cytosorbents Corporation), are hydrophobic neutral resins that are under evaluation or already in clinical application as selective cytokine adsorbents in extracorporeal blood purification. DALI (Fresenius Medical Care, Bad Homburg, Germany) and ReliSorb (Resindion S.r.l.) are both methacrylate-based polymers functionalized with polyacrylate. DALI is clinically applied for whole blood lipid apheresis. As a third negatively charged polymer, we used the cellulose-based adsorbent Cellufine sulfate (Chisso Corporation), while the neutral Cellufine GCL-2000 served as negative control. Prior to the adsorption studies, adsorbents were extensively washed with pyrogen-free 0.9% NaCl and stored at 4°C in saline solution until further use.
2.4. Adsorbent Characterization
Particle morphology was analyzed by scanning electron microscopy (SEM) using a TM-1000 Tabletop Microscope (Hitachi, Tokyo, Japan). Samples were washed with 100 vol% ethanol and dried for 12 h at 100°C in a heating cabinet. Adsorbents were subsequently sputter-coated with gold (Q150R ES, Quorum Technologies). Cellulose-based adsorbents were incubated overnight with 2.5 vol% glutaraldehyde, rinsed with dH2O, and dehydrated with increasing concentrations of ethanol (30 to 100 vol%) before sputter coating.
To determine the specific surface and the pore size distribution, nitrogen adsorption and desorption isotherms were recorded at −196°C and at relative pressures between 0.001 and 1.0 using an ASAP 2010 V2.00 C physisorption analyzer (Micrometrics Instrument Corp., Norcross, USA). The Brunauer-Emmett-Teller (BET) equation  was used to calculate the specific surface area (). The micropore volume (pore size < 2 nm) was calculated with the Horvath-Kawazoe (H-K) method , whereas the mesopore and macropore volume (2–50 and 50–300 nm, resp.) was obtained via the Barrett-Joyner-Halenda method (BJH) . Assuming cylindrical pore geometry, the average pore diameter was calculated as (with maximum adsorbed nitrogen volume). Values for the average particle diameter and the charge density of the negatively charged adsorbents were provided by the manufacturers.
2.5. Adsorption of Recombinant HMGB1
Adsorption of HMGB1 to the different polymers was studied in batch experiments using adsorbent-to-plasma ratios of 1, 5, and 10 vol%. Plasma was spiked with recombinant human HMGB1 to a target concentration of 200 ng/mL and incubated with the adsorbents at 37°C with gentle shaking. Spiked plasma without adsorbent served as a control. Samples were taken after 15 and 60 min and centrifuged immediately at 4600 ×g for 5 min to remove the adsorbents. Supernatants were collected, aliquoted, and stored at −80°C until further analysis. All experiments were conducted in triplicate. HMGB1 was quantified by enzyme-linked immunosorbent assay (ELISA, Shino-Test Corporation, Kanagawa, Japan) according to instructions of the manufacturer.
2.6. Adsorption of HMGB1 Derived from Stimulation of Peripheral Blood Mononuclear Cells
Human peripheral blood mononuclear cells (PBMCs) were isolated from whole blood anticoagulated with heparin (5 IU/mL final concentration) by density gradient centrifugation (Ficoll-Paque PLUS, GE Healthcare, Uppsala, Sweden) as described . Cells were suspended in medium M199 supplemented with 10 vol% human plasma, 0.02 M HEPES, and 100 μM PS. Aliquots of 1 × 106 cells per mL of medium were stimulated with LPS (0.01–1000 ng/mL) for 16 h in HydroCell Surface 24-well plates (1 mL/well) in humidified atmosphere (5 vol% CO2, 37°C). After stimulation, the cells were pelleted by centrifugation, the supernatant (conditioned medium) was harvested, and the concentration of released HMGB1 was quantified by ELISA. Conditioned medium was incubated for 60 min with Cellufine sulfate or PSDVB-16, respectively, at an adsorbent-to-plasma ratio of 5 vol%. Adsorbents were removed by centrifugation and HMGB1 remaining in the supernatant was quantified by ELISA.
3. Results and Discussion
3.1. Physicochemical Characterization of the Adsorbents
The characteristics of the adsorbents used in this study are summarized in Table 1. The neutral polymers PSDVB-16 and PSDVB-30 are mesoporous polystyrene-divinylbenzene copolymers with average pore sizes of 15 and 30 nm, respectively. The smaller mean pore size of PSDVB-16 is reflected by its higher specific surface area in comparison to PSDVB-30. PVP-PSDVB, which is based on polystyrene-divinylbenzene coated with polyvinylpyrrolidone, exhibited the lowest pore diameter of all hydrophobic resins tested.
|n.d.: not determined; PSDVB: polystyrene-divinylbenzene.|
The two anionic methacrylate-based adsorbents DALI and ReliSorb differ not only with respect to their surface morphology , but also with respect to charge density, which is 530 and 300 μequivalents of COOH per mL of dry adsorbent for DALI and ReliSorb, respectively. Cellufine sulfate, the third anionic polymer used in this study, has an approximately tenfold higher charge density.
Adsorption isotherms were obtained by measuring the amount of N2 adsorbed across a wide range of relative pressures at a constant temperature. The isotherms resembled type IV according to the classification by Brunauer et al. , typically occurring on porous adsorbents with pores in the range of 1.5–100 nm. At lower pressures, the slope of the isotherms is given by micropores, while at higher pressures the slope reflects an increased uptake of adsorbate as pores become filled, with the inflection point typically occurring near the completion of the first monolayer (Figure 1). The neutral polystyrene-divinylbenzene-based adsorbents showed a high resulting from the presence of micro-, meso-, and macropores.
The morphology of the adsorbent particles was characterized by scanning electron microscopy (SEM; Figure 2). DALI and ReliSorb, the two methacrylate-based polymers, exhibited a comparably structured inner surface but showed clear differences with respect to their outer surface, which appeared open and porous on scanning electron micrographs for ReliSorb, while it had a closed and smooth appearance for DALI. The polystyrene-divinylbenzene-based resins all had a smooth outer surface but differed with respect to their porosity, which was highest for PSDVB-30 in accordance with nitrogen adsorption measurements.
3.2. Adsorption of Recombinant HMGB1
HMGB1 adsorption was studied both with recombinant human HMGB1 and with HMGB1 derived from stimulated peripheral blood mononuclear cells. Pathological blood levels of HMGB1 have been reported to range between 10 and 150 ng/mL . Therefore, we used a target concentration of 200 ng/mL of recombinant HMGB1 in the adsorption experiments, which are summarized in Figure 3. HMGB1 was efficiently adsorbed by both neutral and anionic polymers. Binding of HMGB1 to neutral PSDVB beads occurs via hydrophobic interactions between the amphipathic adsorbate and the hydrophobic matrix, as confirmed by the negligible HMGB1 adsorption by neutral hydrophilic cellulose beads. Regarding the polystyrene-divinylbenzene-based polymers, HMGB1 adsorption was higher for PSDVB-30 as compared to PSDVB-16, most likely due to a better accessibility of the pores due to the higher average pore diameter. PVP-PSDVB bound significantly less HMGB1 than the uncoated PSDVB polymers under identical experimental conditions despite an equivalent specific surface area. This lower efficacy can be attributed to a smaller average pore diameter as well as to diminished accessibility of the inner surface due to the coating of the polymer with polyvinylpyrrolidone. Adsorption of albumin, the most abundant plasma protein, was evaluated for the 5 vol% batch experiment. Plasma albumin levels were reduced by 1.4% to 3% for the negatively charged hydrophilic polymers and by 8% to 10% for neutral hydrophobic resins (Table 2).
The adsorption of cytokines of higher molecular mass, in particular tumor necrosis factor alpha (TNF-α; 51 kDa), to PVP-PSDVB polymers is considerably reduced due to a lack of accessibility of their inner surface [37, 38]. The same may hold true for HMGB1 (30 kDa), and as discussed further below, its association with a wide range of plasma proteins as well as with microvesicles may additionally influence its binding characteristics. PSDVB-based resins are clinically applied in extracorporeal liver support to remove albumin-bound metabolites such as unconjugated bilirubin [39–41]. Noteworthy, blocking of HMGB1 activity has been shown to improve hepatocyte regeneration after ischemia/reperfusion injury , suggesting that its removal by extracorporeal liver support systems may provide a benefit for liver regeneration.
As a DNA-associated protein, we reasoned that HMGB1 would bind to anionic surfaces via electrostatic interactions. Confirming this assumption, all anionic polymers showed efficient binding of HMGB1, with the highest efficiency for Cellufine sulfate, which has a high negative charge density and a small particle diameter, resulting in a large outer surface. Application of Cellufine sulfate as adsorbent for HMGB1 in rat hemoperfusion models resulted in decreased HMGB1 serum levels and improved survival in rats with ischemia-reperfusion injury [28, 29].
The two methacrylate-based adsorbents bound similar amounts of HMGB1 as Cellufine sulfate after 60 min ( versus versus μg for Cellufine sulfate, DALI, and ReliSorb, resp.). The delayed binding of HMGB1 to DALI and ReliSorb as indicated by the higher remaining concentrations after 15 min may be due to differences in particle size, with the most favourable surface-to-volume ratio for Cellufine sulfate. This indicates rapid binding of HMGB1 to the adsorbent surface, while diffusion and adsorption to functional groups inside the particles occur gradually over time. DALI is clinically applied to remove low-density lipoproteins in patients with familial hypercholesterolemia, and the adsorption of HMBG1 may provide an additional benefit in the setting of atherosclerosis, which has been shown to trigger the release of HMGB1 from macrophages .
3.3. Adsorption of HMGB1 Derived from Stimulated Peripheral Blood Mononuclear Cells
Stimulation of PBMCs with LPS resulted in a time-dependent release of HMGB1 reaching a peak after 16 h. PBMCs treated with increasing LPS concentrations (0.01–1000 ng/mL) for 16 h released HMGB1 in a concentration dependent manner (Figure 4(a)). PBMC-derived HMGB1 was efficiently removed by both adsorbents tested (243 versus 113 ng/mL adsorbent for Cellufine sulfate and PSDVB-16, respectively, for an initial concentration of 13.7 ng/mL and an adsorbent-to-medium ratio of 5 vol%, Figure 4(b)).
Next to the physicochemical parameters of the adsorbent polymers, modifications of HMGB1 are likely to influence its binding to different polymers. Acetylation, phosphorylation, and oxidation are critical for the diverse biological activities of HMGB1. In an inflammatory environment, the production of reactive oxygen species induces HMGB1 oxidation, leading to a loss of its biological activity and restricting its proinflammatory role in a temporal and spatial manner. Since acetylation, phosphorylation, and oxidation induce changes in charge and conformation of HMGB1, they might influence its binding to different polymers. It is, thus, conceivable that adsorbents preferentially deplete certain subsets of HMGB1 with different biological activity.
Finally, HMGB1 is associated with microvesicles from both activated and apoptotic cells . It may be embedded into microvesicles or interact with negatively charged phosphatidylserine residues on the microvesicle surface. In any case, this association influences the adsorption of HMGB1 to porous polymers due to increased size of the adsorbate, and different subsets of HMGB1 may preferentially be associated with microvesicles, again leading to selective depletion of HMGB1 variants.
Neutral and anionic polymers were tested for their capability to remove recombinant as well as PBMC-derived HMGB1 from human plasma. HMGB1 was efficiently adsorbed by negatively charged beads in a time-dependent manner due to electrostatic forces. It also bound to neutral porous polystyrene-based particles via hydrophobic interactions. Unmodified hydrophilic cellulose adsorbed only negligible amounts of the cytokine, despite its large pores and high surface-to-volume ratio, while Cellulose sulfate bound HMGB1 with high efficiency.
Posttranslational modification and/or oxidation of HMGB1 are critical for the regulation of its biological activity. Since these modifications influence the charge as well as the conformation of HMGB1, subsets with different biological activity may show preferential interaction with adsorbent polymers or with plasma proteins deposited on these polymers, which might open a way to selectively deplete HMGB1 subsets with different biological activity.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
The authors are grateful to André Leistner and Aniela Leistner for support with the nitrogen adsorption measurements. This study was funded by the Christian Doppler Society (Christian Doppler Laboratory for Innovative Therapy Approaches in Sepsis).
- H. Yanai, T. Ban, Z. Wang et al., “HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses,” Nature, vol. 462, no. 7269, pp. 99–104, 2009.
- R. Chen, W. Hou, Q. Zhang, R. Kang, X.-G. Fan, and D. Tang, “Emerging role of high-mobility group box 1 (HMGB1) in liver diseases,” Molecular Medicine, vol. 19, no. 1, pp. 357–366, 2013.
- U. Andersson and K. J. Tracey, “HMGB1 is a therapeutic target for sterile inflammation and infection,” Annual Review of Immunology, vol. 29, pp. 139–162, 2011.
- E. Venereau, M. Schiraldi, M. Uguccioni, and M. E. Bianchi, “HMGB1 and leukocyte migration during trauma and sterile inflammation,” Molecular Immunology, vol. 55, no. 1, pp. 76–82, 2013.
- M. Maroso, S. Balosso, T. Ravizza et al., “Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures,” Nature Medicine, vol. 16, no. 4, pp. 413–419, 2010.
- V. Urbonaviciute, B. G. Fürnrohr, S. Meister et al., “Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE,” The Journal of Experimental Medicine, vol. 205, no. 13, pp. 3007–3018, 2008.
- S. Gardella, C. Andrei, D. Ferrera et al., “The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway,” EMBO Reports, vol. 3, no. 10, pp. 995–1001, 2002.
- T. Bonaldi, F. Talamo, P. Scaffidi et al., “Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion,” The EMBO Journal, vol. 22, no. 20, pp. 5551–5560, 2003.
- D. Tang, Y. Shi, R. Kang et al., “Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1,” Journal of Leukocyte Biology, vol. 81, no. 3, pp. 741–747, 2007.
- C. Semino, G. Angelini, A. Poggi, and A. Rubartelli, “NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1,” Blood, vol. 106, no. 2, pp. 609–616, 2005.
- M. Gougeon and M. Bras, “Natural killer cells, dendritic cells, and the alarmin high-mobility group box 1 protein: a dangerous trio in HIV-1 infection?” Current Opinion in HIV and AIDS, vol. 6, no. 5, pp. 364–372, 2011.
- B. Lu, T. Nakamura, K. Inouye et al., “Novel role of PKR in inflammasome activation and HMGB1 release,” Nature, vol. 488, no. 7413, pp. 670–674, 2012.
- B. Lu, H. Wang, U. Andersson, and K. J. Tracey, “Regulation of HMGB1 release by inflammasomes,” Protein and Cell, vol. 4, no. 3, pp. 163–167, 2013.
- L. F. Gentile and L. L. Moldawer, “HMGB1 as a therapeutic target for sepsis: it's all in the timing!,” Expert Opinion on Therapeutic Targets, vol. 18, no. 3, pp. 243–245, 2014.
- H. Yang and K. J. Tracey, “Targeting HMGB1 in inflammation,” Biochimica et Biophysica Acta—Gene Regulatory Mechanisms, vol. 1799, no. 1-2, pp. 149–156, 2010.
- J. Evankovich, S. W. Cho, R. Zhang et al., “High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity,” The Journal of Biological Chemistry, vol. 285, no. 51, pp. 39888–39897, 2010.
- J. H. Youn and J. Shin, “Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion,” Journal of Immunology, vol. 177, no. 11, pp. 7889–7897, 2006.
- H. Schierbeck, H. Wähämaa, U. Andersson, and H. E. Harris, “Immunomodulatory drugs regulate HMGB1 release from activated human monocytes,” Molecular Medicine, vol. 16, no. 9-10, pp. 343–351, 2010.
- J. S. Park, D. Svetkauskaite, Q. He et al., “Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein,” The Journal of Biological Chemistry, vol. 279, no. 9, pp. 7370–7377, 2004.
- I. E. Dumitriu, P. Baruah, A. A. Manfredi, M. E. Bianchi, and P. Rovere-Querini, “HMGB1: guiding immunity from within,” Trends in Immunology, vol. 26, no. 7, pp. 381–387, 2005.
- M. T. Lotze and K. J. Tracey, “High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal,” Nature Reviews Immunology, vol. 5, no. 4, pp. 331–342, 2005.
- M. E. Bianchi, “HMGB1 loves company,” Journal of Leukocyte Biology, vol. 86, no. 3, pp. 573–576, 2009.
- D. Tang and M. T. Lotze, “Tumor immunity times out: TIM-3 and HMGB1,” Nature Immunology, vol. 13, no. 9, pp. 808–810, 2012.
- H. Yanai, T. Ban, and T. Taniguchi, “High-mobility group box family of proteins: ligand and sensor for innate immunity,” Trends in Immunology, vol. 33, no. 12, pp. 633–640, 2012.
- H. Yang, P. Lundbäck, L. Ottosson et al., “Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1),” Molecular Medicine, vol. 18, no. 2, pp. 250–259, 2012.
- E. Venereau, M. Casalgrandi, M. Schiraldi et al., “Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release,” Journal of Experimental Medicine, vol. 209, no. 9, pp. 1519–1528, 2012.
- M. Yumoto, O. Nishida, K. Moriyama et al., “In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration,” Therapeutic Apheresis and Dialysis, vol. 15, no. 4, pp. 385–393, 2011.
- K. Suda, H. Takeuchi, T. Hagiwara et al., “Spherical sulfated cellulose adsorbs high-mobility-group box chromosomal protein 1 in vitro and in vivo,” ASAIO Journal, vol. 56, no. 3, pp. 210–214, 2010.
- T. Yamamoto, T. Ono, T. Ito, A. Yamanoi, I. Maruyama, and T. Tanaka, “Hemoperfusion with a high-mobility group box 1 adsorption column can prevent the occurrence of hepatic ischemia-reperfusion injury in rats,” Critical Care Medicine, vol. 38, no. 3, pp. 879–885, 2010.
- S. Brunauer, P. H. Emmett, and E. Teller, “Adsorption of gases in multimolecular layers,” Journal of the American Chemical Society, vol. 60, no. 2, pp. 309–319, 1938.
- G. Horvath and K. Kawazoe, “Method for the calculation of the effective pore size distribution in molecular sieve carbon,” Journal of Chemical Engineering of Japan, vol. 16, no. 6, pp. 470–475, 1983.
- E. P. Barrett, L. G. Joyner, and P. P. Halenda, “The determination of pore volume and area distributions in porous substances. I. Computations from nitrogen isotherms,” Journal of the American Chemical Society, vol. 73, no. 1, pp. 373–380, 1951.
- A. Schildberger, E. Rossmanith, T. Eichhorn, K. Strassl, and V. Weber, “Monocytes, peripheral blood mononuclear cells, and THP-1 cells exhibit different cytokine expression patterns following stimulation with lipopolysaccharide,” Mediators of Inflammation, vol. 2013, Article ID 697972, 10 pages, 2013.
- R. Weiss, A. Spittler, G. Schmitz, M. B. Fischer, and V. Weber, “Thrombocyte adhesion and release of extracellular microvesicles correlate with surface morphology of adsorbent polymers for lipid apheresis,” Biomacromolecules, vol. 15, no. 7, pp. 2648–2655, 2014.
- S. Brunauer, L. S. Deming, W. E. Deming, and E. Teller, “On a theory of the van der Waals adsorption of gases,” Journal of The American Chemical Society, vol. 62, no. 7, pp. 1723–1732, 1940.
- H. Wang, O. Bloom, M. Zhang et al., “HMG-1 as a late mediator of endotoxin lethality in mice,” Science, vol. 285, no. 5425, pp. 248–251, 1999.
- M. V. Dileo, J. D. Fisher, B. M. Burton, and W. J. Federspiel, “Selective improvement of tumor necrosis factor capture in a cytokine hemoadsorption device using immobilized anti-tumor necrosis factor,” Journal of Biomedical Materials Research B: Applied Biomaterials, vol. 96, no. 1, pp. 127–133, 2011.
- J. D. Fisher, M. V. DiLeo, and W. J. Federspiel, “Investigating cytokine binding using a previously reported TNF-specific aptamer,” Open Journal of Applied Sciences, vol. 2, no. 3, pp. 135–138, 2012.
- V. Weber, I. Linsberger, M. Hauner, A. Leistnr, A. Leistner, and D. Falkenhagen, “Neutral styrene divinylbenzene copolymers for adsorption of toxins in liver failure,” Biomacromolecules, vol. 9, no. 4, pp. 1322–1328, 2008.
- B. K. Meijers, V. Weber, B. Bammens et al., “Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption,” Artificial Organs, vol. 32, no. 3, pp. 214–219, 2008.
- P. Krisper, V. Stadlbauer, and R. E. Stauber, “Clearing of toxic substances: are there differences between the available liver support devices?” Liver International, vol. 31, supplement 3, pp. 5–8, 2011.
- R. Haraba, V. I. Suica, E. Uyy, L. Ivan, and F. Antohe, “Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein,” Cell and Tissue Research, vol. 346, no. 3, pp. 361–368, 2011.
- D. S. Pisetsky, “The expression of HMGB1 on microparticles released during cell activation and cell death in vitro and in vivo,” Molecular Medicine, vol. 20, no. 1, pp. 158–163, 2014.
Copyright © 2014 Carla Tripisciano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.